Global Radionuclide Injection Market, Ву Туре (Саnсеr, Соrоnаrу Аrtеrу Dіѕеаѕе, аnd Оthеrѕ), Аррlісаtіоn (Ноѕріtаlѕ, Сlіnісѕ, аnd Dіаgnоѕtісѕ Сеntеr) - Industry Trends and Forecast to 2029
Radionuclide Injection Market Analysis and Size
According to World Health Organization, 14.1 million cases registered in 2012 of cancer globally. WHO also stated that more than 33% cancer cases are associated with smoking and chewing tobacco. Radionuclide injection is a radioactive chemical used for diagnostic purpose using positron emission tomography (PET). This injection are generally used for diagnosis of cancer and coronary artery disease. Radionuclide injection contains fluoro-D-glucose as its active ingredient and is given intravenously. As soon as it is injected into the body, it raises the level of glucose under pathophysiological circumstances.
Data Bridge Market Research analyses that the radionuclide injection market is expected to undergo a CAGR of 10.00% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Radionuclide Injection Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
???? (??n??r, ??r?n?r? ?rt?r? D??????, ?nd ?th?r?), ???l???t??n (?????t?l?, ?l?n???, ?nd D??gn??t??? ??nt?r) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Sofie Co. (U.S.), The Qu??n'? Health System Corporation (U.S.), ?r??d ???t???? Inc. (U.S.), N?? U?? LLC (U.S.), ????tr?n ?R? (U.S.), Siemens Healthcare GmbH (Germany), ?h?rt??h L?b?r?t?r??? (U.S.), ?r??????n Nu?l??r LLC (U.S.) |
|
Market Opportunities |
|
Market Definition
Radionuclide injection is radioactive substance used for diagnostic purpose with positron emission tomography (PET). Advancement in radiopharmaceutical technologies along with improved hardware and software of PET imaging are the primary factors driving the growth of radionuclide injection market.
Radionuclide Injection Market Dynamics
Drivers
- Developments in radiopharmaceutical technologies
Radionuclide injection market growth is primarily driven by developments in radiopharmaceutical technologies and better PET imaging hardware and software. Additionally, the radionuclide injection market will grow rapidly due to improved diagnostic accuracy and the low risk associated with this injection.
- Upsurge in cancer cases
The radionuclide injection market will expand greatly due to rising cancer and cardiovascular disease rates. The market for radionuclide injection will increase significantly if major industry players engage with local and regional players.
Opportunities
Radionuclides may be used in therapy, and this has been known for many years. Many benign and malignant illnesses have been effectively treated using a variety of radionuclides, including iodine-131, phosphorous-32, strontium-90, and yttrium-90. The recent development of several new radionuclides and radiopharmaceuticals for the treatment of neuroendocrine and other malignant or non-malignant tumours has accelerated the development of this area of nuclear medicine. The discipline of radionuclide therapy is currently in an exciting phase and is set to experience more expansion and advancement in the years to come.
Restraints/Challenges
Radionuclide injection is expensive, which will limit market expansion. The growth of this market would also be hampered by the scarcity of skilled professionals in developing nations.
This radionuclide injection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the radionuclide injection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Radionuclide Injection Market
People have been compelled to embrace difficult norms of social isolation and economic isolation as a result of the global COVID-19 health and economic devastation. To ensure their and their patients' safety, medical staff has been instructed to alter their daily schedules. The use of radionuclide treatment in therapeutic settings has grown. Oncology is where the majority of therapeutic radionuclide techniques are used. Due to co-morbidities and immunosuppression, cancer patients are a particularly weak and at-risk population. Another danger that needs to be taken into account while planning treatments is COVID-19. For these patients, therapeutic, preventative, and supportive measures might need to change. The most common radionuclide therapies involve patients with differentiated thyroid cancer (DTC) who need radioiodine therapy (RAI), patients with neuroendocrine tumours (NETs) who need peptide receptor radionuclide therapy (PRRT), patients with hepatocellular carcinoma (HCC) who need therapy with radiolabelled microspheres, and patients with prostate cancer and bone metastasis who need radionuclide palliative therapy.
Global Radionuclide Injection Market Scope
The radionuclide injection market is segmented on the basis of type, application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
????
- ??n??r
- ??r?n?r? ?rt?r? D??????
- ?th?r?
???l???t??n
- ?????t?l?
- ?l?n???
- D??gn??t??? ??nt?r
Radionuclide Injection Market Regional Analysis/Insights
The radionuclide injection market is analysed and market size insights and trends are provided by country, type, application as referenced above.
The countries covered in the radionuclide injection market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Due to high healthcare infrastructure, North America is expected to dominate the global radionuclide injection market.
Asia-Pacific is expected to grow the market owing to increasing geriatric population and cancer incidences.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Radionuclide Injection Market Share Analysis
The radionuclide injection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to radionuclide injection market.
Some of the major players operating in the radionuclide injection market are:
- Sofie Co. (U.S.)
- The Qu??n'? Health System Corporation (U.S.)
- ?r??d ???t???? Inc. (U.S.)
- N?? U?? LLC (U.S.)
- ????tr?n ?R? (U.S.)
- Siemens Healthcare GmbH (Germany)
- ?h?rt??h L?b?r?t?r??? (U.S.)
- ?r??????n Nu?l??r LLC (U.S.)
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL RADIONUCLIDE INJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL RADIONUCLIDE INJECTION MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL RADIONUCLIDE INJECTION MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PIPELINE ANALYSIS
6. PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 PORTER’S 5 FORCES
6.3 GLOBAL RADIONUCLIDE INJECTION MARKET ANALYSIS
7. INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8. REGULATORY FRAMEWORK
9. GLOBAL RADIONUCLIDE INJECTION MARKET , BY USE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 ABSCESS AND INFECTION
9.2.1.1. GALLIUM CITRATE GA 67
9.2.1.2. INDIUM IN 111 OXYQUINOLINE
9.2.1.3. OTHERS
9.2.2 BLOOD VESSEL DISEASES
9.2.2.1. SODIUM PERTECHNETATE TC 99M
9.2.2.2. AMMONIA N 13
9.2.2.3. IOFETAMINE I 123
9.2.2.4. BICISATE
9.2.2.5. EXAMETAZIME
9.2.2.6. XENON XE 133
9.2.2.7. OTHERS
9.2.3 BRAIN DISEASES
9.2.3.1. FLUDEOXYGLUCOSE F 18
9.2.3.2. INDIUM IN 111 PENTETREOTIDE
9.2.3.3. IOFETAMINE I 123
9.2.3.4. SODIUM PERTECHNETATE
9.2.3.5. OTHERS
9.2.4 CANCER
9.2.4.1. FLUDEOXYGLUCOSE F 18
9.2.4.2. GALLIUM CITRATE GA 67
9.2.4.3. INDIUM IN 111 PENTETREOTIDE
9.2.4.4. METHIONINE C 11
9.2.4.5. RADIOIODINATED IOBENGUANE
9.2.4.6. SODIUM FLUORIDE F 18
9.2.4.7. TECHNETIUM TC 99M
9.2.4.8. OTHERS
9.2.5 HEART DISEASE
9.2.5.1. AMMONIA N 13
9.2.5.2. FLUDEOXYGLUCOSE F 18
9.2.5.3. RUBIDIUM RB 82
9.2.5.4. TECHNETIUM TC 99M
9.2.5.5. OTHERS
9.2.6 KIDNEY DISEASES
9.2.6.1. IODOHIPPURATE SODIUM
9.2.6.2. TECHNETIUM TC 99M
9.2.6.3. OTHER
9.2.7 LIVER DISEASES
9.2.7.1. AMMONIA N 13
9.2.7.2. FLUDEOXYGLUCOSE F 18
9.2.7.3. TECHNETIUM TC 99
9.2.8 LUNG DISEASES
9.2.8.1. KRYPTON KR 81M
9.2.8.2. TECHNETIUM TC 99
9.2.8.3. XENON XE
9.2.9 OTHERS
9.3 THERAPEUTIC NUCLEAR MEDICINE
9.3.1 BRACHYTHERAPY
9.3.1.1. BY TYPE
9.3.1.1.1. LOW-DOSE RATE (LDR)
9.3.1.1.2. HIGH-DOSE RATE (HDR)
9.3.1.1.3. PERMANENT
9.3.1.2. BY RADIOACTIVE MATERIAL
9.3.1.2.1. IODINE-131
9.3.1.2.2. IRIDIUM-192
9.3.1.2.3. IODINE-125
9.3.1.2.4. PALLADIUM-103
9.3.1.2.5. OTHERS
9.3.2 ANTIBODY THERAPY
9.3.2.1. BY TYPE
9.3.2.1.1. ANTIBODY CONJUGATED RADIOIMMUNOTHERAPY
9.3.2.1.1.1 CONVENTIONAL SINGLE-STEP
9.3.2.1.1.2 MULTI-STEP PRETARGETED
9.3.2.1.2. OTHERS RADIOIMMUNOTHERAPY
9.3.2.2. BY RADIOPHARMACUETICAL
9.3.2.2.1. YTTRIUM-90 IBRITUMOMAB TIUXETAN
9.3.2.2.2. IODINE-131
9.3.2.2.3. OTHERS
9.3.3 TARGETED ALPHA THERAPY (TAT)
9.3.3.1. ACTINIUM-225
9.3.3.2. THORIUM-232
9.3.3.3. OTHERS
10. GLOBAL RADIONUCLIDE INJECTION MARKET , BY PARTICLE
10.1 OVERVIEW
10.2 CAESIUM-131
10.3 PALLADIUM-103
10.4 RADIUM-223
10.5 ACTINIUM-225
10.6 LEAD-212
10.7 TECHNETIUM TC 99
10.8 THORIUM-227
10.9 ASTATINE-211
10.10 IODINE-131
10.11 IRIDIUM-192
10.12 IODINE-125
10.13 PALLADIUM-103
10.14 OTHERS
11. GLOBAL RADIONUCLIDE INJECTION MARKET , BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12. GLOBAL RADIONUCLIDE INJECTION MARKET , BY AGE GROUP
12.1 OVERVIEW
12.2 CHILD
12.3 ADULT
12.4 GERIATRIC
13. GLOBAL RADIONUCLIDE INJECTION MARKET , BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.2.1 BY TYPE
13.2.1.1. PUBLIC
13.2.1.2. PRIVATE
13.2.2 BY USE
13.2.2.1. DIAGNOSTIC
13.2.2.2. THERAPEUTICS
13.3 CANCER CARE CENTERS
13.3.1 DIAGNOSTIC
13.3.2 THERAPEUTICS
13.4 RESEARCH AND ACADEMIC INSTITUES
13.4.1 DIAGNOSTIC
13.4.2 THERAPEUTICS
13.5 OTHERS
14. GLOBAL RADIONUCLIDE INJECTION MARKET , BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT SALES
14.3 INDIRECT SALES
15. GLOBAL RADIONUCLIDE INJECTION MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16. GLOBAL RADIONUCLIDE INJECTION MARKET, BY GEOGRAPHY
GLOBAL RADIONUCLIDE INJECTION MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
16.2 EUROPE
16.2.1 GERMANY
16.2.2 FRANCE
16.2.3 U.K.
16.2.4 POLAND
16.2.5 ITALY
16.2.6 SPAIN
16.2.7 RUSSIA
16.2.8 TURKEY
16.2.9 NETHERLANDS
16.2.10 SWITZERLAND
16.2.11 REST OF EUROPE
16.3 ASIA-PACIFIC
16.3.1 JAPAN
16.3.2 CHINA
16.3.3 SOUTH KOREA
16.3.4 INDIA
16.3.5 AUSTRALIA
16.3.6 SINGAPORE
16.3.7 THAILAND
16.3.8 MALAYSIA
16.3.9 INDONESIA
16.3.10 PHILIPPINES
16.3.11 VIETNAM
16.3.12 REST OF ASIA-PACIFIC
16.4 SOUTH AMERICA
16.4.1 BRAZIL
16.4.2 ARGENTINA
16.4.3 REST OF SOUTH AMERICA
16.5 MIDDLE EAST AND AFRICA
16.5.1 SOUTH AFRICA
16.5.2 SAUDI ARABIA
16.5.3 UAE
16.5.4 EGYPT
16.5.5 KUWAIT
16.5.6 ISRAEL
16.5.7 REST OF MIDDLE EAST AND AFRICA
16.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17. GLOBAL RADIONUCLIDE INJECTION MARKET, SWOT AND DBMR ANALYSIS
18. GLOBAL RADIONUCLIDE INJECTION MARKET , COMPANY PROFILE
18.1 ADVANCED ACCELERATOR APPLICATIONS USA, INC.
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 BLUE EARTH DIAGNOSTICS
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPEMENTS
18.3 BRACCO DIAGNOSTICS INC.
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPEMENTS
18.4 CARDINAL HEALTH, INC.
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPEMENTS
18.5 CURIUM US LLC
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPEMENTS
18.6 JUBILANT DRAXIMAGE INC.
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPEMENTS
18.7 ECKERT & ZIEGLER RADIOPHARMA INC.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPEMENTS
18.8 GE HEALTHCARE, INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPEMENTS
18.9 ION BEAM APPLICATIONS S.A.
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPEMENTS
18.10 LANTHEUS MEDICAL IMAGING, INC.
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPEMENTS
18.11 MEDI-RADIOPHARMA LTD.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPEMENTS
18.12 MEDICAL ISOTOPES, INC.
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPEMENTS
18.13 NORDION (CANADA) INC.
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPEMENTS
18.14 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPEMENTS
18.15 ONCOVISION, INC.
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPEMENTS
18.16 PHILIPS HEALTHCARE
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPEMENTS
18.17 RADIOMEDIX, INC.
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPEMENTS
18.18 SIEMENS MEDICAL SOLUTIONS USA, INC.
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPEMENTS
18.19 SPECTRUM DYNAMICS MEDICAL, INC.
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPEMENTS
18.20 TELIX PHARMACEUTICALS LIMITED
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 SOFIE
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 CURIUM
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19. CONCLUSION
20. QUESTIONNAIRE
21. ABOUT DATA BRIDGE MARKET RESEARCH
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
